NuProbe Global, the precision diagnosis firm equipped with multiple proprietary technologies and global research teams, will further promote the industrialization of its genetic testing products with the fresh proceeds.
Recently, NuProbe Global (Chinese: 阅尔基因) announced its completion of Series B financing round valued at 50 million USD.
The round was led by AstraZeneca CICC venture capital (Chinese: 阿斯利康中金医疗产业基金), CR capital magament (Chinese: 华润正大生命科学基金) and the existing investor Panlin capital (Chinese: 磐霖资本).
Haoreng Capital (Chinese: 皓礽资本), Deguan Capital (Chinese: 德观资产), Pappas Capital and the existing investors BioTrack Capital (博远资本), Sequoia, Yonghua Capital (Chinese: 涌铧资本) and Tuobang Capital (Chinese: 拓邦资本) also participated in this deal. Cec Capital (Chinese: 易凯资本) acted as the exlusive financial advisor.
The funding will be used to further accelerate the R&D of the underlying nucleic acid test technology, the development of new genetic testing products, the expansion of commercial team in both China and the US and the registration and approval of several clinical products.
Founded in 2017, NuProbe Global has established close partnerships with leading international companies such as BioNano and G2i Genomics. In 2021, NuProbe Global was granted the business license of class III medical devices. The R&D centre and production base were also completed and opened in Suzhou.